Local and Systemic STAT3 and p65 NF-KappaB Expression as Progression Markers and Functional Targets for Patients With Cervical Cancer.

cervical cancer human papillomavirus immunoevasion immunomodulation nuclear factor – kappa B signal transducer activator of transcription 3

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2020
Historique:
received: 10 08 2020
accepted: 22 10 2020
entrez: 17 12 2020
pubmed: 18 12 2020
medline: 18 12 2020
Statut: epublish

Résumé

Cervical cancer, which main etiologic factor is Human Papillomavirus (HPV) infection, continues to be a burden for public health systems in developing countries. Our laboratory has been working with the hypothesis that signals generated in the tumor microenvironment can modulate local and systemic immune responses. In this context, it would be reasonable to think that tumors create pro-tumoral bias in immune cells, even before they are recruited to the tumor microenvironment. To understand if and how signaling started in the tumor microenvironment can influence cells within the tumor and systemically, we investigated the expression of key proteins in signaling pathways important for cell proliferation, viability, immune responses and tolerance. Besides, we used detection of specific phosphorylated residues, which are indicative of activation for Akt, CREB, p65 NFκB, and STAT3. Our findings included the observation of a significant STAT3 expression increase and p65 NFκB decrease in circulating leukocytes in correlation with lesion grade. In light of those observations, we started investigating the result of the inhibition of STAT3 in a tumor experimental model. STAT3 inhibition impaired tumor growth, increased anti-tumor T cell responses and decreased the accumulation of myeloid cells in the spleen. The concomitant inhibition of NFκB partially reversed these effects. This study indicates that STAT3 and NFκB are involved in immunomodulatory tumor effects and STAT3 inhibition could be considered as therapy for patients with cervical cancer.

Identifiants

pubmed: 33330068
doi: 10.3389/fonc.2020.587132
pmc: PMC7710991
doi:

Types de publication

Journal Article

Langues

eng

Pagination

587132

Informations de copyright

Copyright © 2020 Rossetti, da Silva-Junior, Rodríguez, Alvarez, Stone, Cipelli, Silveira, Beldi, Mota, Margarido, Baracat, Uno, Villa, Carvalho, Yokochi, Rosa, Lorenzi and Lepique.

Références

Nat Rev Cancer. 2019 Feb;19(2):82-96
pubmed: 30578415
Int J Cancer. 2012 Nov 1;131(9):1969-82
pubmed: 22623137
J Immunol. 2011 Aug 1;187(3):1157-65
pubmed: 21709158
Curr Oncol Rep. 2015 Apr;17(4):17
pubmed: 25708801
Gynecol Oncol. 2017 Jun;145(3):584-594
pubmed: 28222899
Nat Rev Clin Oncol. 2019 Oct;16(10):601-620
pubmed: 31160735
Cancer. 2017 Jul 1;123(13):2404-2412
pubmed: 28464289
J Pathol. 1999 Sep;189(1):12-9
pubmed: 10451482
Int J Mol Sci. 2019 Jan 08;20(1):
pubmed: 30625987
J Cell Biochem. 2017 Dec;118(12):4163-4169
pubmed: 28475243
Exp Cell Res. 2001 Jul 15;267(2):205-15
pubmed: 11426939
Oncotarget. 2017 Feb 21;8(8):13400-13412
pubmed: 28077792
Am J Cancer Res. 2020 Jun 01;10(6):1793-1807
pubmed: 32642291
Brief Funct Genomics. 2013 Nov;12(6):489-98
pubmed: 23943603
Oncotarget. 2017 Mar 7;8(10):16755-16764
pubmed: 28187430
Blood. 2006 Jul 15;108(2):525-35
pubmed: 16527895
Int J Mol Sci. 2018 Sep 18;19(9):
pubmed: 30231582
J Leukoc Biol. 2014 Oct;96(4):619-31
pubmed: 24970861
Nature. 2017 Mar 16;543(7645):378-384
pubmed: 28112728
Trends Biochem Sci. 2005 Jan;30(1):43-52
pubmed: 15653325
Clin Immunol. 2006 Nov;121(2):215-26
pubmed: 16959540
Proc Natl Acad Sci U S A. 2007 May 1;104(18):7391-6
pubmed: 17463090
Cancers (Basel). 2019 Nov 21;11(12):
pubmed: 31766350
Curr Opin Struct Biol. 2019 Dec;59:47-53
pubmed: 30901610
Immun Inflamm Dis. 2014 Aug;2(2):63-75
pubmed: 25400927
Sci Rep. 2015 Dec 15;5:18217
pubmed: 26666576
FEBS J. 2015 Jul;282(14):2600-11
pubmed: 25825152
FEBS J. 2007 Jul;274(13):3224-32
pubmed: 17565603
Oncotarget. 2016 Jun 7;7(23):35454-65
pubmed: 26934558
J Immunol. 2001 May 1;166(9):5398-406
pubmed: 11313376
Oncol Lett. 2018 Nov;16(5):6215-6227
pubmed: 30405758
Br J Clin Pharmacol. 2016 Oct;82(4):943-56
pubmed: 27232857
Viruses. 2017 Sep 12;9(9):
pubmed: 28895886
PLoS Pathog. 2019 Jun 21;15(6):e1007835
pubmed: 31226168
J Cell Commun Signal. 2016 Mar;10(1):61-7
pubmed: 26253919
Front Oncol. 2018 Apr 19;8:117
pubmed: 29725585
BMC Infect Dis. 2015 Nov 21;15:541
pubmed: 26589896
Genes (Basel). 2018 Jan 09;9(1):
pubmed: 29315242
Sci Rep. 2017 Aug 21;7(1):9002
pubmed: 28827632
Oncoimmunology. 2015 Feb 03;4(1):e984539
pubmed: 25949866
J Clin Microbiol. 2000 Jan;38(1):357-61
pubmed: 10618116
J Natl Cancer Inst. 2014 Jun 19;106(7):
pubmed: 24948742
Expert Opin Investig Drugs. 2017 Aug;26(8):883-887
pubmed: 28714740
J Immunol. 2013 Jun 1;190(11):5882-93
pubmed: 23630344
J Leukoc Biol. 2019 May;105(5):1041-1054
pubmed: 30811636
J Biol Chem. 2006 Sep 8;281(36):26041-50
pubmed: 16835236
Cancer Res. 1996 Jan 1;56(1):21-6
pubmed: 8548765

Auteurs

Renata A M Rossetti (RAM)

Department of Immunology, Instituto de Ciências Biomédicas, Universidade de Sao Paulo, São Paulo, Brazil.
Department of Radiology and Oncology, Faculdade de Medicina da Universidade de Sao Paulo, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil.

Ildefonso A da Silva-Junior (IA)

Department of Immunology, Instituto de Ciências Biomédicas, Universidade de Sao Paulo, São Paulo, Brazil.

Gretel R Rodríguez (GR)

Department of Immunology, Instituto de Ciências Biomédicas, Universidade de Sao Paulo, São Paulo, Brazil.

Karla L F Alvarez (KLF)

Department of Immunology, Instituto de Ciências Biomédicas, Universidade de Sao Paulo, São Paulo, Brazil.

Simone C Stone (SC)

Department of Immunology, Instituto de Ciências Biomédicas, Universidade de Sao Paulo, São Paulo, Brazil.

Marcella Cipelli (M)

Department of Immunology, Instituto de Ciências Biomédicas, Universidade de Sao Paulo, São Paulo, Brazil.

Caio R F Silveira (CRF)

Department of Immunology, Instituto de Ciências Biomédicas, Universidade de Sao Paulo, São Paulo, Brazil.

Mariana Carmezim Beldi (MC)

Department of Immunology, Instituto de Ciências Biomédicas, Universidade de Sao Paulo, São Paulo, Brazil.

Giana R Mota (GR)

Department of Radiology and Oncology, Faculdade de Medicina da Universidade de Sao Paulo, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil.

Paulo F R Margarido (PFR)

Hospital Universtário, Universidade de Sao Paulo, São Paulo, Brazil.

Edmund C Baracat (EC)

Hospital Universtário, Universidade de Sao Paulo, São Paulo, Brazil.

Miyuki Uno (M)

Biobanco da Rede Acadêmica de Pesquisa do Câncer da Universidade de Sao Paulo, São Paulo, Brazil.

Luisa L Villa (LL)

Department of Radiology and Oncology, Faculdade de Medicina da Universidade de Sao Paulo, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil.

Jesus P Carvalho (JP)

Center for Translational Research in Oncology, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil.

Kaori Yokochi (K)

Department of Radiology and Oncology, Faculdade de Medicina da Universidade de Sao Paulo, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil.

Maria Beatriz S F Rosa (MBSF)

Center for Translational Research in Oncology, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil.

Noely P Lorenzi (NP)

Department of Radiology and Oncology, Faculdade de Medicina da Universidade de Sao Paulo, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil.

Ana Paula Lepique (AP)

Department of Immunology, Instituto de Ciências Biomédicas, Universidade de Sao Paulo, São Paulo, Brazil.

Classifications MeSH